Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

• Egile Nagusiak: Anning Xiong (Egilea), Wei Nie (Egilea), Lei Cheng (Egilea), Hua Zhong (Egilea), Tianqing Chu (Egilea), Runbo Zhong (Egilea), Jun Lu (Egilea), Shuyuan Wang (Egilea), Jianlin Xu (Egilea), Yinchen Shen (Egilea), Feng Pan (Egilea), Baohui Han (Egilea), Xueyan Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Anlotinib is a novel anti-angiogenesis drug. In non-small cell lung cancer (NSCLC), high body mass index (BMI) was not associated with worse survival in patients treated with bevacizumab compared with those with normal or low BMI. However, it remains unknown whether such an association s...